Live Breaking News & Updates on Panc Part

Stay updated with breaking news from Panc part. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

TYME Technologies, Inc. Reports Fourth Fiscal Quarter and Full Year 2022 Financial and Operating Results

25.05.2022 - - $84.0 million in cash and marketable securities as of March 31, 2022 -BEDMINSTER, N.J., May 25, 2022 (GLOBE NEWSWIRE) - TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer . ....

Lisam Wilson , Site Communications Inc , Exchange Commission , Tyme Technologies Inc , Technologies Inc , Fourth Fiscal Quarter , Full Year , Panc Part , Metastatic Pancreatic Cancer , Precision Promise , Private Securities Litigation Reform Act , In Site Communications , Tyme Technologies , Consolidated Statement , Ended March , Comprehensive Loss , Net Loss , Adjusted Net , Year Ended March , Net Loss Per Share , Adjusted Basic , Diluted Net Loss Per ,

Tyme Technologies : Annual Report (Form 10-K)

Tyme-10k 20220331.htm

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

. | May 25, 2022 ....

New York , United States , United Kingdom , Santa Monica , New Jersey , Monte Carlo , Georgetown University , District Of Columbia , Janm Van Tornout , Barbarac Galaini , James Biehl , Jonathan Eckard , Timothyc Tyson , Jan Van Tornout , Frank Mongiello , Sant Chawla , Steve Hoffman , Frank Porfido , Michael Demurjian , Richard Cunningham , Trickett Wendler , Us Congress , Revenue Service , Health Care Reform Lawarealsoinvalid On , Investor Relations Department , Transaction Committee ,

TYME Technologies, Inc. Provides Business Update and Announces Third Fiscal Quarter 2022 Financial a

– Georgetown University and associated Georgetown Medstar Centers continued enrollment in Phase II OASIS trial evaluating the potential benefits of oral SM-88 for patients with metastatic HR+/HER2- breast cancer after treatment with a CDK4/6 inhibitor– On track for mid-2022 full enrollment of HopES trial for SM-88 u. ....

Richie Cunningham , Exchange Commission On , Pancreatic Cancer Action Network Pan , Georgetown Medstar Centers , Tyme Technologies Inc , Company Form , Exchange Commission , Technologies Inc , Georgetown University , Pipeline Program , Joseph Ahmed Foundation , Fiscal Quarter , Recent Highlights , Cancer Trial , Joseph Ahmed , Overall Response Rate , Progression Free , Chief Executive Officer , Precision Promise , Pancreatic Cancer Action Network , Compassionate Use , Panc Part , Private Securities Litigation Reform Act , Consolidated Statement , Net Loss , Adjusted Net ,